Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Iosulamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iosulamide SCHEMBL29401400 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNACYP2C19HIF1AKDM4E | |
| Iosulamide SCHEMBL2109419 | 0.86 | TSHR (0.37) | SMN1; SMN2LMNACYP2C19HIF1A | |
| SCHEMBL11635725 | 0.83 | TSHR (0.35) | SMN1; SMN2LMNA | |
| Metrizoic Acid SCHEMBL1237977 | 0.76 | SMN1; SMN2 (0.78) | SMN1; SMN2LMNACYP2C19HIF1AKDM4E | |
| Metrizoic Acid SCHEMBL30869169 | 0.76 | SMN1; SMN2 (0.78) | SMN1; SMN2LMNACYP2C19HIF1AKDM4E | |
| Metrizoic Acid SCHEMBL2339916 | 0.75 | SMN1; SMN2 (0.76) | SMN1; SMN2LMNACYP2C19HIF1AKDM4E | |
| Diatrizoic Acid SCHEMBL1685085 | 0.74 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAHIF1AKDM4E | |
| Diatrizoic Acid SCHEMBL107036 | 0.74 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAHIF1AKDM4E | |
| Diatrizoic Acid SCHEMBL720469 | 0.74 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAHIF1AKDM4E | |
| SCHEMBL11630200 | 0.73 | MAPK1 (0.43) | SMN1; SMN2LMNACYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 748 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066828-A1 | Humanized Anti-HLA-DR Antibodies | IMMUNOMEDICS, INC. | 2017-03-09 | — | — | US | claimed |
| EP-1521775-B1 | MONOCLONAL ANTIBODY PAM4 AND ITS USE FOR DIAGNOSIS AND THERAPY OF PANCREATIC CANCER | IMMUNOMEDICS INC (US) | 2015-09-09 | — | — | EP | claimed |
| US-8986699-B2 | Anti-CD74 immunoconjugates and methods of use | IMMUNOMEDICS, INC. (US) | 2015-03-24 | — | — | US | claimed |
| US-8846002-B2 | Anti-CD74 immunoconjugates and methods of use | THE OHIO STATE UNIVERSITY (US) | 2014-09-30 | — | — | US | claimed |
| CN-103936859-A | Humanized L243 antibodies | IMMUNOMEDICS INC | 2014-07-23 | — | — | CN | claimed |
| US-8722047-B2 | Humanized anti-HLA-DR antibodies | IMMUNOMEDICS, INC. (US) | 2014-05-13 | — | — | US | claimed |
| US-20130171064-A1 | Anti-CD74 Immunoconjugates and Methods of Use | IMMUNOMEDICS, INC. (US) | 2013-07-04 | — | — | US | claimed |
| US-20130142729-A1 | Anti-CD74 Immunoconjugates and Methods of Use | IMMUNOMEDICS, INC. (US) | 2013-06-06 | — | — | US | claimed |
| EP-2596023-A2 | COMPOSITIONS AND METHODS FEATURING IL-6 AND IL-21 ANTAGONISTS | Beth Israel Deaconess Medical Center, Inc. (US) | 2013-05-29 | — | — | EP | claimed |
| US-8383081-B2 | Anti-CD74 immunoconjugates and methods of use | IMMUNOMEDICS, INC. (US) | 2013-02-26 | — | — | US | claimed |
| WO-2004013180-A2 | ALPHA-FETOPROTEIN IMMU31 ANTIBODIES AND FUSION PROTEINS AND METHODS OF USE THEREOF | IMMUNOMEDICS, INC. (US) | 2004-02-12 | — | — | WO | claimed |
| EP-1372718-A2 | PRODUCTION AND USE OF NOVEL PEPTIDE-BASED AGENTS FOR USE WITH BI-SPECIFIC ANTIBODIES | Immunomedics, Inc. (US) | 2004-01-02 | — | — | EP | claimed |
| WO-2003106497-A1 | MONOCLONAL ANTIBODY PAM4 AND ITS USE FOR DIAGNOSIS AND THERAPY OF PANCREATIC CANCER | IMMUNOMEDICS, INC. (US) | 2003-12-24 | — | — | WO | claimed |
| WO-2003106495-A2 | MONOCLONAL ANTIBODY hPAM4 | IMMUNOMEDICS, INC. (US) | 2003-12-24 | — | — | WO | claimed |
| WO-2003103723-A2 | NEUTROPHIL IMAGING METHODS IN CYCTIC FIBROSIS | IMMUNOMEDICS, INC. (US) | 2003-12-18 | — | — | WO | claimed |
| WO-2003097105-A1 | DRUG PRE-TARGETING BY MEANS OF BI-SPECIFIC ANTIBODIES AND HAPTEN CONSTRUCTS COMPRISING A CARRIER PEPTIDE AND THE ACTIVE AGENT (S) | IMMUNOMEDICS, INC. (US) | 2003-11-27 | — | — | WO | claimed |
| US-20030198595-A1 | Use of bi-specific antibodies for pre-targeting diagnosis and therapy | IMMUNOMEDICS, INC. | 2003-10-23 | — | — | US | claimed |
| US-20030148409-A1 | Direct targeting binding proteins | IBC PHARMACEUTICALS | 2003-08-07 | — | — | US | claimed |
| WO-2003033654-A2 | DIRECT TARGETING BINDING PROTEINS | IMMUNOMEDICS, INC (US) | 2003-04-24 | — | — | WO | claimed |
| WO-2002082041-A2 | PRODUCTION AND USE OF NOVEL PEPTIDE-BASED AGENTS FOR USE WITH BI-SPECIFIC ANTIBODIES | IMMUNOMEDICS, INC. (US) | 2002-10-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030198595-A1 | Use of bi-specific antibodies for pre-targeting diagnosis and therapy | FCGR3B, FCGR2A, MAN2B2 | SMN1; SMN2 3305/4885LMNA 415/4885CYP2C19 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.